Generated by Codex with GPT 5.6 Sol XHigh

Eli Lilly has become the first pharmaceutical company valued above \$1trn, a status usually reserved for technology giants. Its rise rests largely on Zepbound and other GLP-1 medicines, which have turned obesity treatment into one of the industry’s biggest new markets. Yet chief executive Dave Ricks is using that success to pursue a broader ambition: remaking Lilly from a conventional drugmaker into a company built around prevention, direct relationships with patients and reusable technological platforms.

From breakthrough drug to durable advantage

Lilly entered the obesity market more than two years after Novo Nordisk, but overtook its rival through a stronger treatment, fewer side-effects, lower pricing and early investment in manufacturing. Zepbound generated \$4.9bn in its first full year, and Lilly now accounts for roughly three-fifths of American GLP-1 sales.

Competition is intensifying, with more than 120 companies developing obesity drugs. Lilly’s response is to “cover the chessboard” with treatments that offer different balances of effectiveness, tolerability and convenience. It is also spending more than \$50bn to expand production. In a market where demand can outrun the supply of injectable medicines, manufacturing capacity is not merely an operational concern; it is a competitive moat.

The company also treats GLP-1 technology as a platform rather than a single product. The same biological foundation can support medicines that combine multiple hormones, while related injectables can share parts of the manufacturing network. This resembles the logic of a technology platform: each successful product makes the next one easier and cheaper to develop and deliver.

The prevention bet

The larger opportunity lies beyond weight loss. GLP-1 medicines already appear to reduce the risks associated with cardiovascular disease, sleep apnoea and chronic kidney disease. Early research suggests possible benefits for addiction and psychiatric illness as well. Lilly is asking whether medicines can move even further upstream and prevent disease before symptoms appear.

That idea is shaping its research pipeline. Lilly paid \$7.8bn for Centessa Pharmaceuticals, whose work on sleep regulation may have applications beyond narcolepsy. It is also testing whether donanemab, its Alzheimer’s medicine, can delay or prevent the disease in people who do not yet show symptoms.

Prevention, however, clashes with the way health care is financed. Treatment costs arrive immediately, while the savings may take years to appear and may benefit a different insurer. Giving medicines to people who are not yet ill also raises the risk of over-diagnosis and over-treatment. The scientific question of whether a drug works is therefore only part of the challenge; health systems must also decide who should receive it, when and at whose expense.

A more consumer-facing drugmaker

A prevention business must remain close to patients for years. LillyDirect, the company’s online pharmacy, is designed to make prices clearer, simplify access and reduce the friction of navigating America’s fragmented health-care system. More than half of new patients starting Lilly’s GLP-1 treatments now arrive through online channels, including LillyDirect. The shift gives the company a more direct role in the customer experience than pharmaceutical firms traditionally have had.

Lilly is borrowing selectively from Silicon Valley. It wants platforms, faster feedback and simpler transactions, but Ricks warns against systems that eventually serve themselves instead of their users. He is similarly cautious about artificial intelligence. Lilly is building a biomedical AI supercomputer with Nvidia and sharing models with selected biotech firms, yet Ricks argues that current AI does not truly understand biology. Its near-term value may lie less in discovering miracle drugs than in reducing health care’s administrative burden.

Lilly’s transformation is therefore not just a wager on obesity medicines. It is a test of whether scale in science, manufacturing and distribution can support a new pharmaceutical model - one that prevents illness, builds reusable capabilities and treats access as part of the product. The opportunity is enormous, but success will depend as much on payment systems and patient trust as on laboratory breakthroughs.